CD209 (DC-SIGN) Antibody, anti-human, REAfinity™
Synonyms: DC-SIGN, DC-type lectin domain family 4 member L, Dendritic cell-specific ICAM-3-grabbing non-integrin 1, DC-SIGN1
RECOMBINANT
Bioz Star93/100 Bioz rating
18 Citations1 Image
Clone:
REA617 | DCN47.5
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD209 (DC-SIGN) Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
APC-Vio 770
Biotin
FITC
PE
PE-Vio 670
PE-Vio 770
PerCP-Vio 700
Vio Bright B515
Vio Bright V600
Vio Bright V646
VioBlue
Recommended dilution:
1:50
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-124-257, 130-124-304
Description:
Human immature monocyte-derived dendritic cells stained with CD209 (DC-SIGN) antibodies or with the corresponding REA Control (S) antibodies (left peak). Flow cytometry was performed using the MACSQuant® Analyzer. The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Application image
MICS (MACSima Imaging Cyclic Staining) applications
APC
FITC
PE
Fixation:
frozen – Acetone
Species tested:
human
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-124-304, 130-124-257
Testing grade:
Specifications for CD209 (DC-SIGN) Antibody, anti-human, REAfinity™
Overview

Clone REA617 recognizes the CD209 antigen, also known as dendritic cell specific ICAM-3 grabbing non-integrin (DC-SIGN), a type II c-type lectin expressed in dermal and mucous tissue, lymphoid tissue such as tonsil, lymph node, spleen, as well as on monocyte-derived DCs (MoDCs). It is not expressed on DC subsets in peripheral blood, except for a subpopulation of CD14+ cells with a DC-like phenotype. DC-SIGN acts as an adhesion receptor to facilitate interactions between DCs and T cells or DCs and endothelial cells. In addition, it serves as an antigen receptor mediating internalization of ligands for antigen presentation, binding virus such as HIV, HCMV, or Ebola as well as parasites, bacteria, or yeast. HIV-1 uses this feature of DC-SIGN for efficient intrans infection of CD4+ T cells.

Additional information: Clone REA617 displays negligible binding to Fc receptors.

Alternative names

DC-SIGN, DC-type lectin domain family 4 member L, Dendritic cell-specific ICAM-3-grabbing non-integrin 1, DC-SIGN1

Detailed product information

Technical specifications

Clone
REA617
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD209 (DC-SIGN)
Molecular mass of antigen [kDa]
46
Distribution of antigen
dendritic cells, endothelial cells, macrophages, spleen, skin
Entrez Gene ID
RRID
AB_2904825, AB_2784063, AB_2751413, AB_2784062, AB_2751871, AB_2751841, AB_2904826, AB_2819594, AB_2751431, AB_2656261, AB_2656260, AB_2656252, AB_2904823, AB_2904824, AB_2656253, AB_2819609

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD209 (DC-SIGN) Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support